Stock DNA
Pharmaceuticals & Biotechnology
SEK 99 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.74
-269.96%
2.94
Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Jun 2025)
Net Profit:
-27 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.0%
0%
3.0%
6 Months
-8.53%
0%
-8.53%
1 Year
0.88%
0%
0.88%
2 Years
-57.07%
0%
-57.07%
3 Years
-91.05%
0%
-91.05%
4 Years
-93.39%
0%
-93.39%
5 Years
-92.77%
0%
-92.77%
SciBase Holding AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
31.59%
EBIT Growth (5y)
-184.13%
EBIT to Interest (avg)
-43.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.80
Sales to Capital Employed (avg)
0.69
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.36
EV to EBIT
-1.47
EV to EBITDA
-1.53
EV to Capital Employed
14.01
EV to Sales
3.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-952.91%
ROE (Latest)
-276.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
8.80
8.90
-1.12%
Operating Profit (PBDIT) excl Other Income
-21.50
-18.40
-16.85%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-26.60
-27.50
3.27%
Operating Profit Margin (Excl OI)
-2,524.20%
-2,164.40%
-35.98%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.12% vs 3.49% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 3.27% vs -57.14% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
29.70
23.20
28.02%
Operating Profit (PBDIT) excl Other Income
-63.70
-50.50
-26.14%
Interest
0.30
0.40
-25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-61.10
-55.60
-9.89%
Operating Profit Margin (Excl OI)
-2,254.30%
-2,317.50%
6.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 28.02% vs 29.61% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -9.89% vs -28.70% in Dec 2023
About SciBase Holding AB 
SciBase Holding AB
Pharmaceuticals & Biotechnology
SciBase Holding AB is a Sweden-based company engaged in the medical equipment industry. The Company specializes in the manufacture of point of care device, called Nevisense, which is aimed to detect of malignant melanoma. Nevisense analyze suspicious lesions by using Electrical Impedance Spectroscopy (EIS) which is applied as an electrical signal to the skin. The diagnostic product is sold in Nordic countries, Belgium, Germany, Great Britain and Australia.






